N. Widmer

Discipline

Sociologie (2) Psychologie (1) Education (1) Economies et finances (1)

Type de document

Articles (21) Colloques et conférences (8) Recensions (6)

Co-auteur

Date

Source

Mot-clé

Patients (14) Patients (13) modèle (12) Example (12) Pharmacokinetics (12) dosage (11) Treatment (11) Drug monitoring (11) Imatinib (11) plasma (11) pharmacocinétique (10) Methods (10) Pharmacokinetics (10) Methods (10) exposition (9) Drugs (9) Models (9) dose (8) Time (8) Population (8) Analysis (8) Population (8) temps (durée) (7) analyse (7) distribution (7) abords (agglomération) (7) âge (6) Human beings (6) Evaluation (6) Age (6)

Documents écrit par N. Widmer (28) | parle de N. Widmer (0)

Precision oncology by point-of-care therapeutic drug monitoring and dosage adjustment of conventional cytotoxic chemotherapies: A perspective.
M. Briki et al. (2023)
From personalized to precision medicine in oncology: A model-based dosing approach to optimize achievement of imatinib target exposure.
S. Goutelle et al. (2023)
Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation.
K. Dao et al. (2 févr. 2022)
Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: Lessons from the CounterCOVID - imatinib study.
I.H. Bartelink et al. (2021)
Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections.
L.A. Decosterd et al. (10 nov. 2020)
The steps to therapeutic drug monitoring: A structured approach illustrated with imatinib
T. Buclin et al. (2020)
Prescription of sedative drugs during hospital stay: A Swiss prospective study.
L. Schumacher et al.
Biases affecting injected doses of an experimental drug during clinical trials.
N. Perrottet et al. (16 juil. 2016)
Antibiotic consumption in nursing homes of the Canton of Vaud: trends over the years 2009 - 2014
C. Plüss-Suard et al. (2015)
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
V. Gotta et al. (2014)
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
M. Arab-Alameddine et al. (2014)
Towards a new combination therapy for tuberculosis with next generation benzothiazinones.
V. Makarov et al. (2014)
Dosing regimen of gentamicin in neonates: evaluation of current guidelines based on a large population pharmacokinetic analysis
A. Fuchs et al. (2014)
Simulation-based systematic review of imatinib population pharmacokinetics and PK-PD relationships in chronic myeloid leukemia (CML) patients
V. Gotta et al. (2013)
Suivi thérapeutique des concentrations d'inhibiteurs de tyrosine kinase et d'autres médicaments oncologiques = Therapeutisches Drug-Monitoring der Konzentration von Tyrosinkinase-Inhibitoren und anderen Onkologika
N. Widmer (2013)
Population pharmacokinetic study of gentamicin: A retrospective analysis in a large cohort of neonate patients
A. Fuchs et al. (2013)
Probability of achieving optimal molecular response to imatinib in chronic myeloid leukemia (CML) patients: Pharmacokinetic/Pharmacodynamic (PK/PD) relationships observed under field-conditions
V. Gotta et al. (2012)
Pragmatic approach for interpreting antiretroviral drug concentrations based on a systematic review of population pharmacokinetic studies
M. Arab-Alameddine et al. (2012)
The Swiss young pharmacists group: Preparing for the future by examining the past
F. Ledermann et al. (2012)
Benchmarking therapeutic drug monitoring software: A systematic evaluation of available computer tools
A. Fuchs et al. (2012)
Personalized modeling for drug concentration prediction using Support Vector Machine
W. You et al. (2011)
Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): An emerging role for drug blood level testing?
M. von Mehren et al. (2011)
Symposium swissYPG 2011 "La Pharmacie en mutation"
N. Widmer et al. (2011)
Symposium swissYPG 2011 "Die Apotheke im Wandel"
N. Widmer et al. (2011)
Imatinib plasma levels: correlation with clinical benefit in GIST patients.
N. Widmer et al. (2010)

next